Latest Comments

The likely relocation of the EMA is bad news for the pharmaceutical industry and the health of 500 million Europeans

The likely relocation of the EMA is bad news for the pharmaceutical industry and the health of 500 million Europeans

PCR-based C. difficile Cytotoxin assays alone not appropriate for pivotal endpoint measures

PCR-based C. difficile Cytotoxin assays alone not appropriate for pivotal endpoint measures

Newest class of type 2 diabetes drugs continues its push into the US market

Newest class of type 2 diabetes drugs continues its push into the US market

More than just a pretty face: Botox set to combat depression

More than just a pretty face: Botox set to combat depression

Recurring C. difficile infections cause havoc in hospitals in Scotland and England

Recurring C. difficile infections cause havoc in hospitals in Scotland and England

Curing hepatitis C: A double-edged sword for liver transplant candidates?

Curing hepatitis C: A double-edged sword for liver transplant candidates?

Small but mighty: nanotechnology in cancer therapy

Small but mighty: nanotechnology in cancer therapy

Pharma price hiking: why does it happen?

Pharma price hiking: why does it happen?

Targeting of specific patient groups to break into the epilepsy market

Targeting of specific patient groups to break into the epilepsy market

Uncertainty Grows for Immuno-Oncology Therapies in Glioblastoma Multiform

Uncertainty Grows for Immuno-Oncology Therapies in Glioblastoma Multiform

Heading for the future: transplants and the pharma market

Heading for the future: transplants and the pharma market

Supernus Pharmaceuticals expands neurology portfolio with label extension of Trokendi XR

Supernus Pharmaceuticals expands neurology portfolio with label extension of Trokendi XR

Trump’s new FDA Commissioner: A reasonable pick despite conflicts of interest

Trump’s new FDA Commissioner: A reasonable pick despite conflicts of interest

Novo Nordisk’s long-acting growth hormone somapacitan likely to conquer the adult GHD market in Japan

Novo Nordisk’s long-acting growth hormone somapacitan likely to conquer the adult GHD market in Japan

Newron Pharmaceuticals finally gets FDA approval for Parkinson’s medication

Newron Pharmaceuticals finally gets FDA approval for Parkinson’s medication

CRISPR CAS 9 genome editing heralds a revolution in healthcare

CRISPR CAS 9 genome editing heralds a revolution in healthcare

Personalised medicine: a paradigm shift in treatment

Personalised medicine: a paradigm shift in treatment

Pharmacoeconomics: a crushing reality in today’s industry

Pharmacoeconomics: a crushing reality in today’s industry

Ohr Pharmaceuticals is determined to show efficacy for Squalamine despite setbacks

Ohr Pharmaceuticals is determined to show efficacy for Squalamine despite setbacks

Despite widespread legalisation, federal regulations are keeping cannabis research under wraps

Despite widespread legalisation, federal regulations are keeping cannabis research under wraps

WHO appeal for new antibiotics lacks necessary incentives

WHO appeal for new antibiotics lacks necessary incentives